BidaskClub Downgrades Utah Medical Products (NASDAQ:UTMD) to Strong Sell

Share on StockTwits

BidaskClub lowered shares of Utah Medical Products (NASDAQ:UTMD) from a sell rating to a strong sell rating in a research report sent to investors on Tuesday morning, BidAskClub reports.

Separately, ValuEngine upgraded shares of Utah Medical Products from a hold rating to a buy rating in a report on Tuesday, February 4th.

UTMD stock opened at $93.40 on Tuesday. The firm has a 50-day moving average price of $100.70 and a 200-day moving average price of $99.25. The stock has a market capitalization of $346.50 million, a P/E ratio of 23.71 and a beta of 0.78. Utah Medical Products has a 12 month low of $76.60 and a 12 month high of $112.26.

Utah Medical Products (NASDAQ:UTMD) last issued its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $1.01 earnings per share (EPS) for the quarter. The business had revenue of $11.83 million during the quarter. Utah Medical Products had a net margin of 31.40% and a return on equity of 15.10%.

In related news, CEO Kevin L. Cornwell sold 800 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $107.67, for a total value of $86,136.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin L. Cornwell sold 584 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $107.05, for a total transaction of $62,517.20. The disclosure for this sale can be found here. 7.30% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of UTMD. Advisor Group Inc. acquired a new stake in Utah Medical Products during the 4th quarter valued at approximately $38,000. Bank of Montreal Can increased its position in Utah Medical Products by 44.6% during the 4th quarter. Bank of Montreal Can now owns 441 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 136 shares during the period. Citigroup Inc. increased its position in Utah Medical Products by 49.2% during the 4th quarter. Citigroup Inc. now owns 707 shares of the medical instruments supplier’s stock valued at $76,000 after purchasing an additional 233 shares during the period. Denali Advisors LLC increased its position in Utah Medical Products by 2,384.8% during the 4th quarter. Denali Advisors LLC now owns 1,143 shares of the medical instruments supplier’s stock valued at $123,000 after purchasing an additional 1,097 shares during the period. Finally, Nisa Investment Advisors LLC increased its position in Utah Medical Products by 1,116.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,460 shares of the medical instruments supplier’s stock valued at $140,000 after purchasing an additional 1,340 shares during the period. Institutional investors and hedge funds own 76.19% of the company’s stock.

About Utah Medical Products

Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry in the United States, Europe, and internationally. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD, an infant respiratory hood; and DELTRAN PLUS, a blood pressure monitoring system.

Recommended Story: Balanced Fund

Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.